Skip to main content

Table 1 Overview of RCT characteristics

From: Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review

Characteristic

Category

RCT published between

Jan.2004 –Mar. 2014 (n. 9),

N. (%)

RCTs published between

Apr.2014 – Jun.2018 (n. 8),

N. (%)

Total (n. 17),

N. (%)

International (if more than one country)

No

8 (88.9)

8 (100)

16 (94.1)

Yes

1 (11.1)

0 (0)

1 (5.9)

Industry supported (fully or in part)

No

6 (66.7)

7 (87.5)

13 (76.5)

Yes

3 (33.3)

1 (12.5)

4 (23.5)

PRO endpoint

Primary

5 (55.6)

0 (0)

5 (29.4)

Secondary

4 (44.4)

8 (100)

12 (70.6)

Secondary paper on PRO

No

8 (88.9)

8 (100)

16 (94.1)

Yes

1 (11.1)

0 (0)

1 (5.9)

Length of PRO assessment during RCT

Up to 6 months

4 (44.5)

6 (75)

10 (58.8)

Up to 1 year

2 (22.2)

1 (12.5)

3 (17.7)

More than 1 year

3 (33.3)

1 (12.5)

4 (23.5)

Overall study sample size

<=200

7 (77.8)

7 (87.5)

14 (82.3)

> 200

2 (22.2)

1 (12.5)

3 (17.7)